Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373065 | 1.00 | S1PR1 (0.56) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL13875328 | 0.89 | S1PR1 (0.58) | S1PR1ADAMTS5MMP2UTS2R | |
| SCHEMBL4159021 | 0.87 | S1PR1 (0.56) | S1PR1ADAMTS5MMP2UTS2R | |
| SCHEMBL4384846 | 0.86 | S1PR1 (0.59) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4168401 | 0.86 | S1PR1 (0.59) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4169110 | 0.85 | S1PR1 (0.53) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL4166457 | 0.83 | S1PR1 (0.52) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL4164065 | 0.79 | S1PR1 (0.60) | S1PR1MMP2CA2 | |
| SCHEMBL4165496 | 0.78 | S1PR1 (0.52) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4363505 | 0.78 | S1PR1 (0.58) | S1PR1ADAMTS5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ADGRE5, ADGRF1, SELPLG | S1PR1 677/4885ADAMTS5 891/4885MMP2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.